Key Takeaways
- Guidance raised, execution ahead of plan: FY26 PAT grew 108% YoY, surpassing stated commitments, and FY27 guidance calls for 30–40% revenue growth and 50–60% PAT growth, both above the prior year’s trajectory.
- The ANDA engine is scaling fast: Approved ANDAs more than doubled to 51 in one year, with 30+ launches planned over the next few quarters, providing multi-year revenue visibility.
- Apnar acquisition is live but margin-dilutive for now: The 75% stake closed in Q4, revenue started only in April, so the quarter carried ~100 bps of cost without the offsetting top line; FY27 contribution is guided at ₹80–100 cr.
- Emerging markets turned the corner: EBITDA margin hit ~20% in Q4, up from 13% in Q3, driven by product mix and forex gains; management expects the business to sustain at 18–19% and settle at 20–21%.
- What to watch next quarter: The pace of ANDA commercialization, whether Apnar revenue scales to plan, and any movement on the PIC/S approval that unlocks South Africa and Vietnam.
ANDA Portfolio & Launch Visibility
- Portfolio scale doubled: Approved ANDAs rose from 22 in March 2025 to 51 in March 2026, reflecting accelerated execution and a growing pipeline of 27 molecules under development across 60+ strengths.
- Launch cadence locked in: 30+ approved ANDAs, spanning 100+ strengths, are slated for launch over the next few quarters; management expects 90–95% of the 51 ANDAs to be commercialized within six to eight quarters.
- Revenue ramp is gradual: Peak revenue from an ANDA launch takes three to five years, or at least two to three years, so the near-term launches build a multi-year compounding base rather than an immediate spike.
- CGT opportunity is real but unquantified: Management said “quite a bit” of the 30+ launches would qualify as CGT-eligible and some are first-to-launch, but declined to give an exact count on the call.
Shah: “For FY27, our initial outlook indicates revenue growth of approximately 30% to 40% and PAT growth of about 50% to 60%. This confidence is supported by a robust order pipeline and clear visibility on upcoming product launches over the coming quarters.”
Apnar Pharma Integration
- Acquisition closed, shipments started: Senores acquired a 75% stake in Q4 FY26, with the remaining 25% expected by end of this year; the USFDA-approved facility also holds UK MHRA and Health Canada approvals, and two shipments (one US, one UK) were made in the last three months.
- Q4 margin drag, FY27 contribution: Apnar incurred costs in Q4 without revenue, suppressing consolidated EBITDA margin by ~100 bps; commercial shipments began in April, and full-year FY27 revenue is guided at ₹80–100 cr, with a two-to-three-year target of ₹180–200 cr requiring some production expansion.
- Capacity decision pending: The fourth OSD line originally planned for Atlanta has been deferred after the Apnar acquisition; management will decide in the next two quarters whether to install that line in the US or expand at Apnar’s Baroda facility.
Shah: “So, for the full year, we expect Apnar to give us about INR80 crores to INR100 crores of revenues from that particular plant. And that has already started giving us from this last month onwards.”
Emerging Markets Turnaround
- Margin inflection in Q4: Emerging markets EBITDA margin improved from 13% in Q3 to ~20% in Q4, driven by a product mix shift toward niche molecules and realized forex gains of ~₹3 cr; per-unit realization jumped 60–70% from ₹1.20 to ₹1.90 on the same capacity.
- FY27 outlook: Revenue is projected at ~₹180 cr, with EBITDA margin expected to sustain at 18–19% and possibly add 100–200 bps to settle at 20–21%; the business is now cash flow positive.
- Next margin leg depends on scale: Management indicated that once emerging markets revenue crosses ₹220–250 cr, another 200–300 bps margin jump is expected, though no timeline was attached to that threshold.
- PIC/S approval opens new doors: The emerging market facility is in the process of obtaining PIC/S approval by June/July 2026, which would enable entry into South Africa, Vietnam, and other mid-tier markets.
Shah: “Probably once we cross about INR220 crores to INR250 crores, then you will probably see another 200 basis points, 300 basis points jump in emerging market margins.”
US Strategy & Front-End Buildout
- Moving toward direct presence: Senores is building front-end sales and marketing in the US because acquired products are largely unapproved, and accessing the market directly accelerates commercialization; the cash requirement for launching approved products is significantly lower than developing new ones.
- Amerisyn JV opens government channel: A strategic joint venture signed in April enables entry into US federal government, Veterans Affairs, and military procurement markets via FSS tenders; the JV is budgeted at ₹70–80 cr average revenue with EBITDA profitability upwards of 40%.
- Long-term US ambition: Management is targeting at least ₹2,500–3,000 cr of revenue from the US in the next three to four years, with an aspiration to reach ₹3,000–4,000 cr.
- Zoraya adds distribution heft: Acquired as a step-down subsidiary in Q3 FY26, Zoraya Pharmaceuticals bolsters US marketing and distribution capabilities.
Shah: “As a company, we are building at least INR2,500 crores to INR3,000 crores of revenue just coming out of the US in the next three to four years’ timeframe.”
Margins, Mix & Working Capital
- Blended margin guidance held at 29–31%: Management is comfortable with this range for FY27 and does not want to raise it despite aiming to grow margins, citing geopolitical and macroeconomic uncertainties; the guidance is described as conservative, with 35% top-line growth called “very courageous” in today’s environment yet “the minimum achievable.”
- CDMO vs own-product mix stable for now: The split remains roughly 50–53% own products and 47–48% CDMO-CMO; own products are expected to increase this year as new launches come through, which would be margin-accretive.
- Working capital stretched by Apnar: Consolidated working capital days rose to 187, but excluding Apnar the figure is ~104 days; the acquisition added sales-not-yet-reflected to the balance sheet, inflating the metric temporarily.
- Unbilled revenue grew on new launches: Other financial assets rose from ₹116 cr to ₹172 cr, driven by profit share on B2B cost-plus-margin models booked as income and parked as a financial asset until realized, typically within one to six months.
- Tax rate normalizes higher: The effective tax rate moved from 17% to 23.6% as US taxation at 20–21% and Indian taxation at 26% both now apply; Apnar trade began earning, requiring tax provisioning, while the prior lower rate reflected old carry-forward losses in the US.
Majmudar: “In today’s scenario, to talk about 35% growth is itself very courageous, I would say. But I think we have enough visibility to at least say that this could be regarded as the minimum achievable.”
India Branded Generics & Other Bets
- India business scaled 5x: Revenue grew roughly five times in FY26, driven by field force expansion and a broader portfolio; supplies to marquee hospitals have commenced.
- FY27 investment budget: The branded generic business is budgeted at ₹60–70 cr this year, with a medical representative count target of ~200.
- Sterile manufacturing capex begins: IPO funds of ~₹100 cr will be deployed toward sterile manufacturing development starting this year and continuing for the next couple of years; total FY27 capex is guided at ~₹200 cr, with the balance going to other plants and maintenance.
- Sourced business flatlining: No further growth is expected from the sourced/spot business segment, which has remained broadly consistent.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 30% to 40% YoY | FY27 |
| PAT growth | 50% to 60% YoY | FY27 |
| Blended EBITDA margin | 29% to 31% | FY27 |
| Apnar Pharma revenue contribution | ₹80 cr to ₹100 cr | FY27 |
| Emerging markets revenue | ~₹180 cr | FY27 |
| Emerging markets EBITDA margin | Sustain at 18–19%, settle at 20–21% | FY27 |
| ANDA launches | 30+ approved ANDAs (100+ strengths) | Next few quarters |
| Remaining ANDA commercialization | 90–95% of 51 ANDAs | Next 6–8 quarters |
| PIC/S approval for emerging market facility | Approval obtained | June/July 2026 |
| Apnar remaining 25% stake acquisition | Stake acquired | By end of this year |
| Amerisyn JV revenue | ₹70–80 cr average (range ₹50–100 cr) | FY27 |
| Amerisyn JV EBITDA profitability | Upwards of 40% | FY27 |
| FY27 capex | ~₹200 cr (₹100 cr injectables, ₹100 cr other) | FY27 |
| Normalized tax rate | ~23% average | Ongoing |
| Capacity expansion decision (4th OSD line location) | Decision made | Next two quarters |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Consolidated revenue | ₹190 cr, +66% YoY |
| Consolidated EBITDA | ₹62 cr, >3x YoY |
| EBITDA margin | 32.7%, +1,151 bps YoY |
| PAT after tax and minority interest | ~₹32 cr, +78% YoY |
| FY26 consolidated revenue | ₹664 cr, +62% YoY |
| FY26 consolidated EBITDA | ~₹200 cr, more than doubled YoY |
| FY26 EBITDA margin | 30%, +527 bps YoY |
| FY26 PAT after tax and minority interest | ₹122 cr, +108% YoY |
| FY26 operating cash flow | ~₹75 cr, significant improvement over last year |
| FY27 revenue growth guidance | 30% to 40% |
| FY27 PAT growth guidance | 50% to 60% |
| FY27 EBITDA margin guidance | 29% to 31% |
| Regulated markets revenue | ₹118 cr, +83% YoY |
| Emerging markets revenue | ₹20 cr, +26% YoY |
| India branded generics revenue | ~₹9 cr, doubled YoY |
| Approved ANDAs | 51, covering >150 product strengths, up from 22 in March 2025 |
| ANDAs commercially launched | 20 launched; 30 approved ANDAs covering >100 strengths to be launched over next few quarters |
| Molecules under development | ~27 molecules, involving >60 strengths |
| Working capital days | 187 days; ex-Apnar ~104 days |
| Apnar Pharma expected FY27 revenue | ₹80 cr to ₹100 cr |
| Emerging markets FY27 revenue projection | ~₹180 cr |
| Emerging markets Q4 EBITDA margin | 18% to 19% |
| CDMO-CMO revenue share | 47% to 48% of total; own products 50% to 53% |
| FY26 capex | ~₹230 cr, including ~₹65 cr for ANDA acquisition |
| FY27 expected capex | ~₹200 cr, including ₹100 cr for injectable and ₹100 cr for other plants and maintenance |
| Amerisyn JV FY27 revenue budget | ₹70 cr to ₹80 cr on average |